Stroke. 1999;30:2272-2276
(Stroke. 1999;30:2272-2276.)
© 1999 American Heart Association, Inc.
Clinical Course, Surgical Management, and Long-Term Outcome of Moyamoya Patients With Rebleeding After an Episode of Intracerebral Hemorrhage
An Extensive Follow-Up Study
Yasuko Yoshida, MD, PhD;
Takashi Yoshimoto, MD, PhD;
Reizo Shirane, MD, PhD
Yoshiharu Sakurai, MD, PhD
From the Department of Neurosurgery, Tohoku University School of Medicine
(Y.Y., T.Y., R.S.), and the Neurosurgical Department, Stroke Center, Sendai
National Hospital (Y.S.), Sendai, Japan.
 |
Abstract
|
|---|
Background and
PurposeRevascularization surgery for
moyamoya
patients is believed to prevent cerebral ischemic
attacks by
improving cerebral blood flow. However, measures preventing
the
occurrence of hemorrhagic moyamoya in patients have not yet
been
established in the literature due to the low rate of
hemorrhage
onset as well as the originally limited numbers of
patients
with moyamoya disease, poor understanding of the clinical
course
of rebleeding, correct surgical management, and long-term
outcome.
We present here the results of an overall survey of
patients
with hemorrhagic moyamoya disease in a district of Miyagi
Prefecture
in Japan and examine their clinical course, efficacy of
revascularization
surgery, and long-term
outcome.
MethodsThis study included 28 moyamoya patients with
episodes of intracranial hemorrhage between 1976 and 1988. The
mean follow-up period was 14.2 years. There were 4 males and 24
females, aged 7 to 69 years (mean 39.2 years). Cerebral angiography and
CT scans were performed for all patients. Surgical treatment was
performed in 19 patients (67.9%), and 10 patients (35.7%) underwent
revascularization surgery. We observed the clinical
course of all 28 patients. We also studied the relationship between the
efficacy of surgical treatment and long-term outcome.
ResultsFive of the 28 patients (17.9%) died of the initial
intracranial hemorrhage, and 2 patients died of other causes.
Rebleeding occurred in 6 of the remaining 21 patients (28.6%). The
interval to rebleeding ranged from 2 to 20 years (mean 7.3 years). Of
these 6 patients, 4 died of rebleeding. Rebleeding was observed in 1 of
8 patients who underwent bypass surgery and in 5 of 13 patients who did
not, which suggested that rebleeding was less likely to occur in
patients who had undergone bypass surgery. However, there was no
significant difference in rebleeding ratio or mortality between
patients with and those without revascularization
surgery (P>0.05).
ConclusionsIn this study, we compiled the results of meticulous
follow-up conducted over the past 10 years for patients with
hemorrhagic moyamoya disease. Because hemorrhagic moyamoya
disease is known for its high rate of mortality at the time of
rebleeding and often causes rebleeding long after the initial episode
(as much as 20 years later), implementation of long-term preventive
measures for rebleeding is necessary. This suggests that a long-term
prospective study of a large number of patients with hemorrhagic
moyamoya disease is required to determine whether bypass surgery
prevents rebleeding of hemorrhagic moyamoya disease.
Key Words: cerebral revascularization intracerebral hemorrhage moyamoya disease
 |
Introduction
|
|---|
Since Suzuki first reported "moyamoya" disease in
1969,
1 the
number of patients with diagnosed moyamoya
disease in Japan,
where the disease is most frequently observed, has
reached approximately
3900. Many articles concerning its diagnosis,
pathological examination,
treatment, and prognosis have appeared.
Revascularization surgery
for moyamoya disease
caused by intracranial internal carotid
artery occlusion is believed to
prevent cerebral ischemic attacks
by improving cerebral blood
flow,
2 3 4 5 and bypass surgery
is actively performed for
patients who have the disease after
an ischemic attack. On the
other hand, the frequency of onset
of moyamoya disease with
intracranial hemorrhage is reported
to be 26.2%. The cause of
hemorrhage is said to be failure of
moyamoya blood vessels
resulting from hemodynamic stress.
6
Because
improvement of cerebral circulatory metabolism was
minimal and
no preventive effect on rebleeding was recognized in the
literature,
many neurosurgeons have been performing conservative
treatment.
7 However, as a result of progress made by
recent studies of
cerebral circulatory metabolism in
understanding the pathology
of moyamoya disease, an increasing
number of neurosurgeons are
performing bypass surgery for patients with
hemorrhagic moyamoya
disease, on the assumption that decrease in
hemorrhagic stress
on moyamoya blood vessels will lead to
prevention of rebleeding.
Nevertheless, with the limited number of
cases and short period
of observation of clinical course, measures to
prevent rebleeding
in patients with moyamoya disease have yet not
been established.
7 8 9 10 11 The study by Suzuki and
Takaku
1 of moyamoya disease
began in Miyagi
Prefecture, which has a population of 2.35 million.
Since then, we have
registered all the patients with the disease
in this region and
followed them. We present here results of
an overall survey of
patients with hemorrhagic moyamoya disease
in a district of Miyagi
Prefecture in Japan and examine their
clinical course, efficacy of
revascularization surgery, and
long-term outcome.
This study represents part of a therapeutic
survey of
hemorrhagic moyamoya disease, and we examined the
preventive effect
of bypass surgery on rebleeding based on its
results.
 |
Subjects and Methods
|
|---|
Patients
This study included 111 moyamoya patients seen from 1976 to
1988
and was based on cerebral angiography performed at 18 institutions
participating
in the Miyagi Stroke Study Group. All patients were
followed
up for >10 years, from onset until 1998. Patients with
pseudo-moyamoya
disease or other systemic diseases were excluded.
Intracranial
lesions caused by moyamoya disease were all confirmed
by CT
scans. Of these 111 patients, 28 (25.2%) presented with
intracranial
hemorrhage. There were 4 males and 24 females (sex
ratio 1:6)
aged 7 to 69 years (mean 39.2 years). Five patients were
aged
<19 years and 23 were >20 years (Figures 1

and 2

, Table
1

). The clinical course,
therapeutic methods, and long-term
outcome of these 28 patients
were investigated.

View larger version (74K):
[in this window]
[in a new window]
|
Figure 1. Case distribution of moyamoya disease in
Miyagi Prefecture in Japan from 1976 to 1988 (n=111, 41 males and 70
females). All cases were diagnosed by cerebral angiography performed at
18 institutions participating in the Miyagi Stroke Study Group. All
patients were followed up for >10 years, from onset until 1998.
|
|

View larger version (38K):
[in this window]
[in a new window]
|
Figure 2. Patient age and disease type at onset. Peak of the
age at first bleeding is in the third and fourth decades of life.
|
|
Types of Hemorrhagic Episodes
Types of hemorrhage in the above 28 patients included 7
intracerebral hemorrhages, 10
intraventricular hemorrhages, 6
intracerebral hemorrhages with
intraventricular hemorrhage, and 5
subarachnoid hemorrhages (Table 2
). Five of the 28 patients (17.9%) died
of hemorrhage at first admission (Table 3
).
Surgical Treatment
Eighteen of the 28 hemorrhagic moyamoya patients were
transferred to 4 major facilities with neurosurgical departments, where
they underwent surgical treatment, including ventricular
drainage in 6, hematoma evacuation in 1, aneurysmal clipping in
3, and ventriculo-peritoneal shunting in 2 patients. Of these patients,
10 (35.7%) underwent revascularization surgery for
16 hemispheres: 7 patients with encephalo-duro-arterio-synangiosis
(EDAS), 1 hemisphere in 1 patient with encephalo-myo-synangiosis (EMS),
1 hemisphere in 1 patient with STA-MCA anastomosis, and 2 hemispheres
in 1 patient with STA-MCA anastomosis combined with EDAS (Table 2
). All the patients were followed up from 1976 to 1998, over a
period ranging from 10 to 22 years (mean 14.2 years). The 7 patients
who died at first admission were excluded.
 |
Results
|
|---|
Rebleeding
Excluding the 7 patients who died at first admission, 6 of the
remaining
21 patients (28.6%), including 1 male and 5 females,
suffered
rebleeding. The interval from the initial episode of
rebleeding
ranged from 2 to 20 years (mean 7.3 years): <2 years for
2
patients, from 2 to 5 years for 2, from 10 to 20 years for
1, and at 20
years for 1. Rebleeding tended to increase within
5 years after the
first hemorrhagic episode (Figure 3

). Patient
age ranged from 49 to
67 years (mean 54.3 years). Types of rebleeding
were as follows: 3
intracerebral hemorrhages, 2
intraventricular
hemorrhages, and 1
subarachnoid hemorrhage (Table 4

). Five of
the 6 rebleeding patients
(83.3%) died during hospitalization.
The mortality of rebleeding was
significantly higher than that
of first bleeding (17.9%) (Table 3

).

View larger version (34K):
[in this window]
[in a new window]
|
Figure 3. Interval from initial episode of rebleeding.
Rebleeding tends to be common within 5 years after the first bleeding,
although some cases of rebleeding occur after a long period.
|
|
Effect of Revascularization Surgery
Rebleeding occurred in 5 of 13 patients who underwent no
revascularization surgery (38.5%). Four of the
five died of rebleeding. Rebleeding occurred in 1 of 8 patients who
underwent revascularization surgery (12.5%); this
patient also died of rebleeding. The mortality rate attributed to
rebleeding did not differ between patients with and those without
bypass surgery. The rebleeding ratio was 12.5% for patients with
bypass surgery and lower than the 38.5% for those without bypass
surgery. However, there was no significant difference in rebleeding
ratio between patients with and without
revascularization surgery (P>0.05,
2 test) (Table 3
).
Long-Term Outcome
Of the 21 patients, 6 (28.6%) died of rebleeding and 2 died of
other causes. Fourteen patients (66.7%) attained long-term survival,
including 6 patients with revascularization surgery
and 8 without revascularization surgery (Figure 4
). The survival rates were 75.0%
and 61.5% for patients with and without
revascularization surgery, respectively. There was
no significant difference (P>0.05,
2 test) in survival rates between the 2
groups. The mortality rates were 25.0% and 38.5% for patients with
and without revascularization surgery,
respectively. In this case as well there was no significant difference
between the 2 groups (P>0.05,
2
test) (Table 3
).

View larger version (53K):
[in this window]
[in a new window]
|
Figure 4. Long-term outcome of hemorrhagic patients. Seven
(25.0%) died at first admission, 5 (23.8%) died of rebleeding, and 2
died of other causes. Fourteen patients, including 1 with rebleeding,
survived.
|
|
 |
Discussion
|
|---|
For treatment of childhood moyamoya disease, various types of
revascularization
surgery have been reported, and
both nonanastomotic and anastomotic
bypass surgeries have been
demonstrated to improve cerebral
circulation.
2 3 4 5
Superiority of anastomotic bypass surgery
to nonanastomotic bypass
surgery with respect to rapid improvement
of cerebral blood flow after
operation has also been reported
for adult moyamoya
patients.
2 5 However, unlike the ischemic
type of
moyamoya disease, prevention by surgical treatment of
rebleeding in
hemorrhagic moyamoya disease has not been
confirmed.
7 8 9 10 11 Although
revascularization surgery appears to improve
cerebral
collateral circulation and to reduce the
hemodynamic disturbance
in moyamoya
vessels, reduction of the occurrence of rebleeding
in hemorrhagic
moyamoya patients after surgical treatment is
difficult to assess
due to lack of long-term postoperative follow-up
data. Houkin et
al
9 reported no significant difference in the
incidence of
rebleeding for patients treated with various types
of surgical
revascularization over a mean 6.4 years of
follow-up.
However, we noted that the rebleeding ratio tended to be
lower
in the group of patients with bypass surgery than in the group
without
the surgery, as indicated by our study. Yet, there was no
significant
difference between them. Additionally, we found that
patients
undergoing bypass surgery appeared to have less rebleeding
than
patients in a nonbypass surgery group. Recently, Fujii
et
al
8 reported an assessment of bypass surgery for patients
with
hemorrhagic moyamoya disease (a summary of the results
reported
by the Research Committee on Spontaneous Occlusion of the
Circle
of Willis of the Ministry of Health and Welfare in Japan in
1997)
and concluded that there was no significant difference in the
incidence
of rebleeding between types of surgical treatment. The
present
study also found no significant prevention of rebleeding by
revascularization
surgery in patients with
hemorrhagic moyamoya disease, although
the rebleeding rate in the
surgery group (11.1%) tended to be
lower than that in the nonsurgery
group (38.5%), even when postoperative
follow-up was extended to 14.3
years. The present study showed
that the prognosis of rebleeding in
patients with hemorrhagic
moyamoya disease was extremely poor, with
5 of 6 patients dying.
Also, some patients experienced rebleeding as
long as 20 years
after the initial bleeding. This was not mentioned in
previous
reports. Therefore, the most important objective treatment for
hemorrhagic
moyamoya disease is long-term prevention of rebleeding.
Unfortunately,
even long-term follow-up for >10 years in this study
also
revealed no correlation between the incidence of rebleeding
and
surgical method. A major cause of this lack of correlation
is that, in
order to examine results of elaborate long-term
follow-up, the area for
investigation was limited to Miyagi
Prefecture, which further narrowed
the already-limited number
of cases. As indicated by the existing
reports, we consider
it difficult to calculate bypass surgery's
preventive effect
on rebleeding based on the past cases, taking account
of various
biases, such as adaptation to surgery and surgical
methods.
The incidence of moyamoya disease is generally <1 in
100 000 individuals, but in Japan it is reported to be much higher.
However, even with the study results available in Japan, it is
difficult to prove that bypass surgery has a preventive effect on
rebleeding. Prospective studies of large numbers of patients may
be necessary to achieve further advances in the field of moyamoya
disease. Because therapeutic methods vary depending on medical
institutions, the overall characteristics of moyamoya disease and
effective therapeutic strategy are difficult to assess, particularly
for hemorrhagic moyamoya patients. Because patients have undergone
revascularization surgery with different methods,
results of the assessment of the incidence of rebleeding may be
unclear. Appropriate comparisons between groups of large numbers of
patients with the same therapeutic method are thus important. Although
the clinical course, surgical management, and long-term outcome of
moyamoya disease are still unclear, despite its being considered a
single entity for more than 30 years, we can summarize the present
findings for our patients with hemorrhagic moyamoya disease as
follows. (1) Peak age of first bleeding is during the third and fourth
decades of life. (2) Rebleeding tends to be common within 7.3 years
after the first bleeding, although some cases of rebleeding occur after
a long period. In some cases, rebleeding occurred after 20 years. (3)
There is still no clear evidence that
revascularization surgery significantly prevents
rebleeding in patients with hemorrhagic moyamoya disease, even in
our study, with observation performed over a mean of 14.2 years. (4) A
preventive effect of bypass surgery on rebleeding is expected. However,
a long-term prospective study that targets a large number of patients
is necessary, with evaluation of cerebral circulatory
metabolism.
 |
Acknowledgments
|
|---|
This work was supported by grants from the Research Committee
on
Spontaneous Occlusion of the Circle of Willis of the Ministry
of Health
and Welfare of Japan (1999). We wish to thank Dr Su
Ching Chan for his
expert help in preparation of the manuscript.
 |
Footnotes
|
|---|
Reprint requests to Yasuko Yoshida, MD, PhD, Department of Neurosurgery,
Tohoku University School of Medicine, 1-1 Seiryo-cho, Aoba-ku,
Sendai 980-8574, Japan.
Received July 1, 1999;
revision received August 23, 1999;
accepted August 23, 1999.
 |
References
|
|---|
-
Suzuki J, Takaku A. Cerebral vascular Moyamoya
disease: a disease showing abnormal net-like vessels in base of brain.
Arch Neurol. 1969;20:288299.[Medline]
[Order article via Infotrieve]
-
Karasawa J, Kikuchi H, Furuse S, Kawamura J, Sasaki T.
Treatment of moyamoya disease with STA-MCA anastomosis.
J Neurosurg. 1978;49:679688.[Medline]
[Order article via Infotrieve]
-
Karasawa J, Kikuchi H, Furuse S, Sasaki T, Yoshida Y,
Ohnishi H, Taki W. A surgical treatment of moyamoya disease
encephalo-myo-synangiosis. Neurol Med Chir (Tokyo).
1977;17(part I):2937.
-
Yoshida YK, Shirane R, Yoishimoto T. Non-anastomotic
bypass surgery for childhood moyamoya disease using dural pedicle
insertion over the brain surface combined with EGMS. Surg
Neurol. 1999;51:404411.[Medline]
[Order article via Infotrieve]
-
Mizoi K, Kayama T, Yoshimoto T, Nagamine Y. Indirect
revascularization for moyamoya disease: is
there a beneficial effect for adult patients? Surg Neurol. 1996;45:541549.[Medline]
[Order article via Infotrieve]
-
Ikezaki K, Fukui M, Inamura T, Kinukawa N, Wakai K,
Ono Y. The current status of the treatment for hemorrhagic type
moyamoya disease based on a 1995 nationwide survey in Japan.
Clin Neurol Neurosurg. 1997;99:183186.
-
Aoki N. Cerebrovascular bypass surgery for the
treatment of Moyamoya disease: unsatisfactory outcome in the
patients presenting with intracranial hemorrhage.
Surg Neurol. 1993;40:372377.[Medline]
[Order article via Infotrieve]
-
Fujii K, Ikezaki K, Irikura K, Miyasaka Y, Fukui M.
The efficacy of bypass surgery for the patients with hemorrhagic
moyamoya disease. Clin Neurol Neurosurg. 1997;99:194195.
-
Houkin K, Kamiyama H, Abe H, Takahashi A, Kuroda S.
Surgical therapy for adult Moyamoya disease: can surgical
revascularization prevent the recurrence of
intracranial hemorrhage? Stroke. 1996;27:13421346.[Abstract/Free Full Text]
-
Saeki N, Nalazaki S, Kubota M, Yamaura A, Hoshi S,
Sunada S, Sunami K. Hemorrhagic type moyamoya disease. Clin
Neurol Neurosurg. 1997;99:196201.[Medline]
[Order article via Infotrieve]
-
Okada Y, Shima T, Nishida M, Yamane K, Yamada T,
Yamanaka C. Effectiveness of superficial temporal arterymiddle
cerebral artery anastomosis in adult moyamoya disease: cerebral
hemodynamics and clinical course in ischemic
and hemorrhagic varieties. Stroke. 1998;29:625630.[Abstract/Free Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
H. Jeong, Y. Kim, W Yoon, S. Joo, S. Lee, and Y. Park
Moyamoya syndrome associated with systemic lupus erythematosus
Lupus,
July 1, 2008;
17(7):
679 - 682.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
D.M. Walz, R.F. Woldenberg, and A. Setton
Pseudoaneurysm of the Anterior Spinal Artery in a Patient with Moyamoya: An Unusual Cause of Subarachnoid Hemorrhage
AJNR Am. J. Neuroradiol.,
August 1, 2006;
27(7):
1576 - 1578.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. J. Koebbe and M. B. Horowitz
A Rare Case of a Ruptured Middle Meningeal Aneurysm Causing Intracerebral Hematoma in a Patient with Moyamoya Disease
AJNR Am. J. Neuroradiol.,
April 1, 2004;
25(4):
574 - 576.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Morioka, J.-I. Hamada, T. Kawano, T. Todaka, S. Yano, Y. Kai, and Y. Ushio
Angiographic Dilatation and Branch Extension of the Anterior Choroidal and Posterior Communicating Arteries Are Predictors of Hemorrhage in Adult Moyamoya Patients
Stroke,
January 1, 2003;
34(1):
90 - 95.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K M El Ramahi and H M Al Rayes
Systemic lupus erythematosus associated with moyamoya syndrome
Lupus,
October 1, 2000;
9(8):
632 - 636.
[Abstract]
[PDF]
|
 |
|